Active substanceSildenafilSildenafil
Similar drugsTo uncover
  • Viagra®
    pills inwards 
    Pfizer Inc.     USA
  • Viagra®
    pills inwards 
    Pfizer Inc.     USA
  • Viassan-LF
    pills inwards 
    LEKFARM, SOOO     Republic of Belarus
  • Viathine
    pills inwards 
  • VIVAYRA®
    pills inwards 
  • Vizarsin®
    pills inwards 
  • Vizarsin® Ku-tab®
    pills inwards 
  • Wilderegra
    pills inwards 
    ATOLL, LLC     Russia
  • Dynamics
    pills inwards 
  • Dynamic Forward
    films inwards 
  • Invida ODP
    films inwards 
  • Maxigra
    pills inwards 
  • Olmax Strong
    pills inwards 
    AKTAVIS GROUP, AO     Iceland
  • Revacio®
    pills inwards 
    Pfizer Inc.     USA
  • Rijamp
    pills n / az. 
  • Silafil
    pills inwards 
    Hemofarm AD     Serbia
  • Silden®
    pills inwards 
    Sopharma, AO     Bulgaria
  • Sildenafil
    pills inwards 
  • Sildenafil
    pills inwards 
    FARMAKTIV, LLC     Russia
  • Sildenafil
    pills inwards 
    VERTEKS, AO     Russia
  • Sildenafil VERTEX
    pills inwards 
    VERTEKS, AO     Russia
  • Sildenafil Cardio
    pills inwards 
    NORTH STAR, CJSC     Russia
  • Sildenafil SZ
    pills inwards 
    NORTH STAR, CJSC     Russia
  • Taxiere®
    pills inwards 
    Zentiva as.     Czech Republic
  • Tornetis®
    pills inwards 
    Sandoz d.     Slovenia
  • Erexel®
    pills inwards 
       
  • EFFEX® Sildenafil
    pills inwards 
    EVALAR, CJSC     Russia
  • Dosage form: & nbspTabscesses dispersible in the oral cavity.
    Composition:

    Each tablet, dispersible in the oral cavity, 50 mg contains:

    active substance: sildenafil citrate 70.2 mg, at recalculation of 50 mg of sildenafil;

    Excipients: lactose monohydrate 63.4 mg; silicon dioxide colloidal 17,3 mg; mannitol 25C 56.6 mg; hypromellose 28.5 mg; butyl methacrylate; dimethylaminoethyl methacrylate and methyl methacrylate copolymer [1:2:1] 64,6 mg; polysorbate-80 2.0 mg; mannitol 200SD 207.4 mg; microcrystalline cellulose 30,0 mg; crospovidone 30.0 mg; aspartame 18.0 mg; flavoring peppermint (truffled peppermint special) 6.0 mg; magnesium stearate 6.0 mg.

    Each a tablet dispersible in the oral cavity, 100 mg contains:

    active substance: sildenafil citrate 140.5 mg, in terms of 100 mg of sildenafil;

    Excipients: lactose monohydrate 126.9 mg; silicon colloid dioxide 34.6 mg; mannitol 25 C 113.2 mg; hypromellose 57.0 mg; butyl methacrylate, dimethylaminoethyl methacrylate and methyl methacrylate copolymer [1:2:1] 129,1 mg; polysorbate-80 3.9 mg; mannitol 200SD 414.8 mg; microcrystalline cellulose 60.0 mg; crospovidone 60.0 mg; aspartame 36.0 mg; flavoring peppermint (truffled peppermint special) 12.0 mg; magnesium stearate 12.0 mg.

    Description:

    White or almost white, round, flat tablets with bevelled edges, with a depression in the center on both sides, with the smell of mint. A small surface roughness of the tablet is allowed.

    Pharmacotherapeutic group:erectile dysfunction remedy - PDE5-inhibitor
    ATX: & nbsp

    G.04.B.E   Drugs for the treatment of erectile dysfunction

    G.04.B.E.03   Sildenafil

    Pharmacodynamics:

    Sildenafil is a potent selective inhibitor of cyclic guanosine monophosphate (cGMP) -specific phosphodiesterase type 5 (PDE5).

    Mechanism of action

    The realization of the physiological mechanism of erection is associated with the release of nitric oxide (NO) in the cavernous body during sexual stimulation. This, in turn, leads to an increase in the level of cGMP, subsequent relaxation of the smooth muscle tissue of the cavernous body and an increase in blood flow.

    Sildenafil does not have a direct relaxing effect on an isolated cavernous body in humans, but enhances the effect NO by inhibiting PDE5, which is responsible for the degradation of cGMP.

    A mandatory condition for the effectiveness of sildenafil is sexual stimulation.

    Sildenafil is selective for PDE5 in vitro, its activity against PDE5 is higher than that of other known isoenzymes of phosphodiesterase: PDE6 - 10-fold; FDE1 - more than 80 times; PDE2, PDE4, PDE7-PDE11 - more than 700 times. Sildenafil is 4000 times more selective for PDE5 than FDES, which is of paramount importance, since FDEZ is one of the key enzymes in the regulation of myocardial contractility.

    Pharmacokinetics:

    The pharmacokinetics of sildenafil in the recommended dose range is linear.

    Suction. Sildenafil quickly absorbed after ingestion. Absolute bioavailability is about 40% (25-63%). After a single dose of 100 mg of sildenafil, the mean maximum concentration (FROMmax) free sildenafil in blood plasma is approximately 18 ng / ml. FROMmOh when administered on an empty stomach is reached within 30-120 minutes (an average of 60 minutes). When taken in combination with fatty foods, the rate of absorption decreases: the time to reach the maximum concentration (Tmax) is increased by 60 min, and Cmax decreases by an average of 29%.

    Distribution. The volume of distribution of sildenafil averages 105 liters. Binding sildenafil and its main circulating N-detylated metabolite with plasma proteins is about 96% and does not depend on the total drug concentration. 90 minutes after ingestion, less than 0.0002% of the dose of sildenafil was found in the sperm of healthy volunteers.

    Metabolism. Sildenafil metabolized mainly in the liver under the action of cytochrome isoenzymes CYP3A4 (main path) and CYP2C9. The main circulating active metabolite formed as a result N-detylation of sildenafil, undergoes further metabolism. By the selectivity of action on PDE, the metabolite is comparable with sildenafil, and its activity in relation to PDE5 in vitro is approximately 50% of the activity of sildenafil. The concentration of the metabolite in the blood plasma is about 40% of the concentration of sildenafil. N-detylated metabolite undergoes further transformation; the final half-life (T1/2) is about 4 hours.

    Excretion. The total clearance of sildenafil is 41 l / h, and the final T1/2 - about 3-5 hours. After oral administration sildenafil is excreted as metabolites, mainly through the intestine (about 80% of the dose), and to a lesser extent - by the kidneys (about 13% of the dose).

    Pharmacokinetics in specific patient groups

    Elderly patients. In elderly patients (over 65 years), the clearance of sildenafil is reduced, and the concentration of free sildenafil in blood plasma is approximately 40% higher than in young (18-45 years). Age does not have a clinically significant effect on the incidence of side effects.

    Impaired renal function. With mild and moderate renal failure, with creatinine clearance (CK) of 30-80 ml / min, the pharmacokinetics of sildenafil after single ingestion at a dose of 50 mg does not change. In severe renal insufficiency (CC <30 ml / min), the clearance of sildenafil decreases, which leads to an increase in the area under the pharmacokinetic curve "concentration-time" (AUC) on 100% and CmOh on 88% compared with the indicators for normal kidney function in patients of the same age group.

    Violation of the function of the liver. In patients with cirrhosis of Class A and B liver according to Child-Pugh classification, clearance of sildenafil decreases, which leads to an increase AUC (84%) and CmOh (47%) compared with patients with normal liver function of the same age group.The pharmacokinetics of sildenafil in patients with severe impairment of liver function have not been studied.

    Indications:

    Treatment of erectile dysfunction characterized by an inability to achieve or maintain an erection penis sufficient for a satisfactory sexual intercourse. Sildenafil is effective only with sexual stimulation.

    Contraindications:

    - Hypersensitivity to sildenafil or to any other component of the drug;

    - application in combination with donators of nitric oxide, nitrates or nitrites in any form;

    - joint use with other drugs to treat erectile dysfunction, since the safety and efficacy of combination therapy have not been studied (see section "Special instructions");

    - severe violations of liver function;

    - severe renal failure (CK <30 mL / min);

    - severe arterial hypotension (systolic blood pressure (BP) less than 90 mm Hg, diastolic blood pressure less than 50 mm Hg);

    - loss of vision in one eye due to anterior ischemic optic neuropathy of non-arterial genesis (see section "Special instructions");

    - hereditary degenerative diseases of the retina of the eye (hereditary retinitis pigmentosa);

    - co-administration with HIV-1 and HIV-2 inhibitor of proteas with ritonavir;

    - patients with rare hereditary diseases of galactose intolerance, lactase deficiency, glucose-galactose malabsorption (the preparation contains lactose monohydrate) or phenylketonuria (the drug contains aspartame);

    - men who are not recommended for sexual activity (for example, patients with severe cardiovascular diseases - unstable angina, severe heart failure, heart attack or stroke, suffered in the previous 6 months);

    - age under 18 years (effectiveness and safety not established);

    - application in women.

    Carefully:

    Arterial hypertension (more than 170/100 mm Hg); arterial hypotension; life-threatening arrhythmias; obstruction of the left ventricular outflow tract (aortic stenosis, hypertrophic obstructive cardiomyopathy) or multiple systemic atrophy syndrome; anatomical deformities of the penis (angulation, cavernous fibrosis or Peyronie's disease); diseases predisposing to the development of priapism (multiple myeloma, leukemia, sickle cell anemia); simultaneous administration of alpha-blockers; diseases accompanied by bleeding,or exacerbation of peptic ulcer of the stomach and duodenum; violations of liver function (class A and B according to the Child-Pugh classification); episodes of the development of anterior non-artery ischemic neuropathy of the optic nerve in the anamnesis.

    Pregnancy and lactation:

    Not intended for use on recorded indications in women.

    Dosing and Administration:

    Inside, regardless of food intake.

    Tablets, dispersible in the oral cavity, fragile - do not take them with wet hands, since the tablet can begin to dissolve. Keep in your mouth until completely dissolved, you can drink it with liquid. It is not recommended to mix the tablet in your mouth with food. When using sildenafil with fatty foods, the effect of the drug may develop later than when it is applied on an empty stomach.

    The recommended dose for most adult patients is 50 mg about 1 hour before sexual activity. With regard to efficacy and tolerability, the dose can be increased to 100 mg. The maximum recommended dose is 100 mg. The maximum recommended frequency of application is once a day.

    Sildenafil is effective only with sexual stimulation.

    Guidelines for the use of a drug packed in a blister containing 4 tablets

    Remove the tablet as follows:

    1. Bend the blister along the line of the rupture.

    2. Open the blister by gently pulling the edge of the foil.

    3. Carefully remove the tablet.

    4. Immediately put the tablet on the tongue and keep in your mouth for a few seconds until completely absorbed, you can drink it with liquid.

    Special patient groups

    Impaired renal function. With a mild and moderate degree of renal failure (CK 30-80 ml / min) dose adjustment is not required.

    Dysfunction of the liver. Since the excretion of sildenafil is disrupted in patients with impaired liver function (for example, with cirrhosis of the liver), the initial dose in patients with hepatic insufficiency is 25 mg. In Rijamp, the dosage is 25 mg. To obtain the indicated dose, it is necessary to use the drug of another manufacturer.

    Taking into account the effectiveness and tolerability, the dose can be increased to 50 mg and then to 100 mg.

    Elderly patients. A dose adjustment is not required.

    Side effects:

    Usually the side effects of sildenafil are weak or moderate and are transient.

    According to WHO, the side effects are classified in relation to their developmental frequency as follows: very often (> 1/10), often (1/10 - 1/100), infrequently (1/100 - 1/1000), rarely (1 / 1000 - 1/10 000), very rarely (<1/10 0000) appointments, including individual cases, and the frequency is unknown (can not be determined from available data).

    Allergic reactions: infrequently - reactions of hypersensitivity (including skin rash), allergic reactions.

    From the sense organs: often - blurred vision, impaired vision, cyanopsy; infrequently - pain in the eyes, photophobia, photopsy, chromatopsy, reddening of eyes / injections of sclera, change in brightness of light perception, mydriasis, conjunctivitis, eye hemorrhage, cataract, tearing device failure, sudden decrease or loss of hearing, tinnitus, pain in ears; rarely - edema of the eyelids and adjacent tissues, dry eyes, the presence of iridescent circles in the field of view around the light source, increased eye fatigue, vision of objects in yellow color (xanthopsia), vision of objects in red (erythropsy), conjunctival hyperemia, mucosal irritation shells of the eyes, unpleasant sensations in the eyes; frequency unknown - non-arteritis anterior ischemic optic nerve neuropathy (NPINZN), retinal vein occlusion,visual field defects, diplopia, temporary loss of vision or blurred vision, increased intraocular pressure, retinal edema, retinal vascular diseases, vitreous detachment / vitreal traction.

    From the cardiovascular system: often - "tides"; infrequently - tachycardia, palpitations, lowering blood pressure, increased heart rate, unstable angina, atrioventricular block, myocardial ischaemia, cerebral thrombosis, cardiac arrest, cardiac failure, abnormalities in electrocardiogram readings, cardiomyopathy; rarely - atrial fibrillation.

    On the part of the organs of hematopoiesis: infrequently - anemia, leukopenia.

    From the side of metabolism: infrequently - a feeling of thirst, swelling, gout, uncompensated diabetes mellitus, hyperglycemia, peripheral edema, hyperuricemia, hypoglycemia, hypernatremia.

    From the respiratory system: often - nasal congestion; infrequently - epistaxis, rhinitis, asthma, dyspnea, laryngitis, pharyngitis, sinusitis, bronchitis, increased sputum volume, increased cough; rarely - a feeling of tightness in the throat, dryness of the mucous membrane of the nasal cavity, swelling of the nasal mucosa.

    From the digestive system: often - nausea, indigestion; infrequently - gastroesophageal reflux disease, vomiting, abdominal pain, dryness of the oral mucosa, glossitis, gingivitis, colitis, dysphagia, gastritis, gastroenteritis, esophagitis, stomatitis, deviation "liver" functional test of a fault, rectal bleeding; rarely - hypoesthesia of the oral mucosa.

    From the side of the musculoskeletal system: often - pain in the back; infrequently - myalgia, pain in the extremities, arthritis, arthrosis, tendon rupture, tenosynovitis, bone pain, myasthenia gravis, synovitis.

    From the genitourinary system: infrequently - cystitis, nocturia, breast enlargement (males), incontinence, hematuria, abnormal ejaculation, genital edema, anorgasmia, haemospermia, penile tissue damage; rarely - a prolonged erection and / or priapism.

    From the central and peripheral nervous system: very often - headache; often - dizziness; infrequently - drowsiness, migraine, ataxia, hypertonus, neuralgia, neuropathy, paresthesia, tremor, vertigo, symptoms of depression, insomnia, unusual dreams, increased reflexes, hypoesthesia; rarely - convulsions, repeated convulsions, fainting.

    From the skin: infrequent - skin rash, hives, herpes simplex, pruritus, increased sweating, skin ulceration, contact dermatitis, exfoliative dermatitis; frequency is unknown - Stevens-Johnson syndrome, toxic epidermal necrolysis.

    Other: infrequent - fever, facial swelling, photosensitivity reaction, shock, asthenia, fatigue, pain of different locations, chills, accidental falls, pain in the chest, accidental trauma; rarely - irritability.

    Cardiovascular complications

    During the postmarketing use of sildenafil, adverse events such as severe cardiovascular complications (including myocardial infarction, unstable angina, sudden cardiac death, ventricular arrhythmia, hemorrhagic stroke, transient ischemic attack, hypertension and hypotension) were reported for the treatment of erectile dysfunction. who had a temporary connection with the use of sildenafil. Most of these patients, but not all of them, had risk factors for cardiovascular complications. Many of these adverse events were observed soon after sexual activity, and some of them were noted after taking sildenafil without subsequent sexual activity.It is not possible to establish the presence of a direct link between the observed undesirable phenomena and these or other factors.

    Visual disorders

    In rare cases, during the post-marketing application of all PDE5 inhibitors, including sildenafil, non-arteritis anterior ischemic optic neuropathy (NPINZN) was reported - a rare disease and the cause of a decrease or loss of vision. Most of these patients had risk factors, in particular, a reduction in the ratio of the diameter of the excavation and the optic disc ("stagnant disk"), age over 50 years, diabetes, hypertension, coronary heart disease, hyperlipidemia and smoking. In the observational study, it was assessed whether the recent use of preparations of the class of PDE5 inhibitors with the acute onset of NPINZH was related. The results indicate an approximately 2-fold increase in the risk of NPIIV within 5 half-lives after the use of the PDE5 inhibitor. According to the published literature, the annual incidence of NPIH is 2.5-11.8 cases per 100 000 men aged ≥ 50 years in the general population.It should be recommended to patients in the event of a sudden loss of vision to stop sildenafil therapy and immediately consult a doctor. Persons who already had a case of NPINZ have an increased risk of recurrence of NPINZN. Therefore, the physician should discuss this risk with such patients, and discuss with them the potential risk of adverse effects of PDE5 inhibitors. PDE5 inhibitors, including sildenafil, these patients should be used with caution and only in situations where the expected benefit outweighs the risk.

    When sildenafil was used in doses exceeding the recommended levels, the adverse events were similar to those noted above, but were usually more common.

    Overdose:

    Symptoms: with a single admission sildenafila in a dose of up to 800 mg, adverse events were comparable to those when taking the drug in lower doses, but were more common, namely: headache, flushing of the skin to the face, dyspepsia, nasal congestion, rhinitis.

    Treatment: symptomatic. Hemodialysis does not accelerate the clearance of sildenafil, since the latter actively binds to plasma proteins and is not excreted by the kidneys

    Interaction:

    The metabolism of sildenafil occurs mainly under the action of cytochrome isoenzymes CYP3A4 (main path) and CYP2C9 (an additional route), so inhibitors of these isoenzymes can reduce the clearance of sildenafil, and inductors, respectively, increase the clearance of sildenafil. There was a decrease in clearance of sildenafil with simultaneous use of cytochrome isoenzyme inhibitors CYP3A4 (ketoconazole, erythromycin, cimetidine).

    Cimetidine (800 mg), a nonspecific inhibitor of the cytochrome isoenzyme CYP3A4, with a joint admission with sildenafil (50 mg) causes an increase in the concentration of sildenafil in plasma by 56%.

    A single dose of 100 mg of sildenafil together with erythromycin (500 mg / day 2 times a day for 5 days), a moderate inhibitor of the cytochrome isoenzyme CYP3A4, on the background of achieving a constant concentration of erythromycin in the blood, leads to an increase AUC sildenafil by 182%.

    When co-administered sildenafil (once 100 mg) and saquinavir (1200 mg / day in 3 divided doses), an HIV protease inhibitor and cytochrome isoenzyme CYP3A4, against the background of achieving a constant concentration of saquinavir in the blood CmOh sildenafil increased by 140%, a AUC increased by 210%. Sildenafil does not affect the pharmacokinetics of saquinavir.

    More potent inhibitors of cytochrome isoenzyme CYP3A4, such as ketoconazole and itraconazole, can cause and stronger changes in the pharmacokinetics of sildenafil.

    Simultaneous use of sildenafil (once 100 mg) and ritonavir (500 mg twice a day), an HIV protease inhibitor and a strong inhibitor of cytochrome P450, with the achievement of a constant concentration of ritonavir in the blood leads to an increase in CmOh sildenafil by 300% (4 times), a AUC - by 1000% (11 times). After 24 hours, the concentration of sildenafil in the blood plasma is about 200 ng / ml (after a single application of only sildenafil - 5 ng / ml). Simultaneous use of sildenafil and ritonavir is contraindicated.

    If sildenafil take in recommended doses of patients receiving simultaneously strong inhibitors of the cytochrome isoenzyme CYP3A4, then CmOh free sildenafil does not exceed 200 nM, and the drug is well tolerated.

    A single dose of antacid (hydroxide / magnesium hydroxide, aluminum) did not affect the bioavailability of sildenafil.

    In studies involving healthy volunteers with simultaneous use of an endothelin receptor antagonist, bosentan (isoenzyme inducer CYP3A4 (moderate), CYP2C9 and, possibly, CYP2C19) and sildenafil in equilibrium concentrations there was a decrease AUC and CmOh sildenafil and an increase in AUC and CmOh bosentan. It is assumed that the simultaneous use of sildenafil with powerful inducers CYP3A4, such as rifampicin, can lead to a greater decrease in the concentration of sildenafil.

    Inhibitors of cytochrome isoenzyme CYP2C9 (tolbutamide, warfarin), cytochrome isoenzyme CYP2D6 (SSRIs, tricyclic antidepressants), thiazide and thiazide-like diuretics, ACE inhibitors, and calcium antagonists have no effect on the pharmacokinetics of sildenafil.

    Azithromycin (500 mg / day for 3 days) does not affect AUC, FROMmOh, TmOh, rate constant and T1/2 sildenafil or its main circulating metabolite.

    Effect of sildenafil on other drugs

    Sildenafil is a weak inhibitor of cytochrome P450 - 1A2, 2C9, 2C19, 2 isoenzymesD6, 2E1 and 3A4 (inhibitory molar concentration IC50> 150 μmol). When taking sildenafil in recommended doses, its CmOh is about 1 μmol, so it is unlikely that sildenafil can affect the clearance of the substrates of these isoenzymes.

    Sildenafil enhances the hypotensive effect of nitrates both with prolonged use of the latter, and when they are prescribed for acute indications. In this regard, the use of sildenafil in combination with nitrates or donators of nitric oxide is contraindicated.

    At simultaneous reception α(4 or 8 mg) and sildenafil (50 or 100 mg) in patients with benign prostatic hyperplasia with stable hemodynamics, the mean additional decrease in systolic BP / diastolic BP (SAD / dAD) in the supine position was 9/5 and 8 / 4 mm of mercury. Art. respectively, and in the standing position - 11/4 and 4/5 mm Hg. Art. respectively. We report rare cases of development in these patients of symptomatic postural hypotension, manifested as dizziness (without syncope). Individual sensitive patients receiving α- adrenoblockers, simultaneous use of sildenafil can lead to symptomatic hypotension.

    Signs of significant interaction with tolbutamide (250 mg) or warfarin (40 mg), which are metabolized by the cytochrome isoenzyme CYP2C9, it is not revealed.

    Sildenafil (100 mg) does not affect the pharmacokinetics of HIV protease, saquinavir and ritonavir inhibitors, which are substrates of the cytochrome isoenzyme CYP3A4, at their constant level in the blood.

    The simultaneous use of bosentan and sildenafil in equilibrium concentrations increases AUC and CmOh bosentan by 49.7% and 42% respectively.

    Sildenafil (50 mg) does not cause an additional increase in bleeding time when taking acetylsalicylic acid (150 mg).

    Sildenafil (50 mg) does not increase the hypotensive effect of alcohol in healthy volunteers at CmOh Alcohol in the blood averaged 0.08% (80 mg / dL).

    In patients with arterial hypertension, there was no evidence of interaction between sildenafil (100 mg) and amlodipine. The average additional decrease in blood pressure in the prone position is 8 mm Hg. (SAD) and 7 mm Hg. (DAD).

    The use of sildenafil in combination with antihypertensive drugs does not lead to additional side effects.

    Special instructions:

    To diagnose erectile dysfunction, determine their possible causes and choose an adequate treatment, you must collect a complete medical history and conduct a thorough physical examination. Remedies for the treatment of erectile dysfunction should be used with caution in patients with anatomical deformation of the penis (angulation,cavernous fibrosis, Peyronie's disease), or in patients with risk factors for priapism - sickle cell anemia, multiple myeloma, leukemia (see section "C caution '").

    During postmarketing studies, cases of development of prolonged erection and priapism were reported. If the erection persists for more than 4 hours, you should immediately seek medical help. If priapism therapy has not been performed immediately, it can lead to damage to the penile tissue and an irreversible loss of potency.

    Drugs intended for the treatment of erectile dysfunction should not be prescribed to men for whom sexual activity is undesirable.

    Sexual activity represents a certain risk in the presence of heart disease, so before starting any therapy for erectile dysfunction, the doctor should refer the patient to a cardiovascular system examination. Sexual activity is undesirable in patients with heart failure, unstable angina, suffered in the last 6 months myocardial infarction or stroke, life-threatening arrhythmias, arterial hypertension (BP> 170/100 mm Hg.) or hypotension (blood pressure <90/50 mm Hg) (see sections "With caution, "" Contraindications " respectively). In clinical studies of sildenafil, there was no difference in the incidence of myocardial infarction (1.1 per 100 people per year) or cardiovascular death rate (0.3 per 100 people per year) in patients who received sildenafil, compared with patients receiving placebo.

    Cardiovascular complications

    During the postmarketing use of sildenafil, adverse events such as severe cardiovascular complications (including myocardial infarction, unstable angina, sudden cardiac death, ventricular arrhythmia, hemorrhagic stroke, transient ischemic attack, hypertension and hypotension) were reported for the treatment of erectile dysfunction. who had a temporary connection with the use of sildenafil. Most of these patients, but not all of them, had risk factors for cardiovascular complications. Many of these adverse events were observed soon after sexual activity, and some of them were noted after taking sildenafil without subsequent sexual activity.

    It is not possible to establish the presence of a direct link between the observed undesirable phenomena and these or other factors.

    Hypotension

    Viagra has systemic vasodilatory effect resulting in a transient decrease in blood pressure that is not clinically significant phenomenon and does not lead to any consequences in most patients. Nevertheless, before the appointment of sildenafil, the physician should carefully evaluate the risk of possible undesirable manifestations of vasodilating action in patients with the corresponding diseases, especially against the background of sexual activity. Increased susceptibility to vasodilators is observed in patients with obstruction of the left ventricular outflow tract (aortic stenosis, hypertrophic obstructive cardiomyopathy), as well as with a rare syndrome of multiple systemic atrophy, manifested severe violation of the regulation of blood pressure from the autonomic nervous system. Since the combined use of sildenafil and alpha-blockers can lead to symptomatic hypotension in selected sensitive patients, sildenafil should be administered with caution to patients taking alpha-blockers (see.section "Interaction with other drugs "). To minimize the risk of postural hypotension in patients taking a-adrenoblockers, the use of sildenafil should be started only after the stabilization of hemodynamic parameters in these patients has been achieved. The doctor should inform patients about what actions should be taken in case of symptoms of postural hypotension.

    Visual disorders

    In rare cases, during the post-marketing application of all PDE5 inhibitors, including sildenafil, non-arteritis anterior ischemic optic neuropathy (NPINZN) was reported - a rare disease and the cause of a decrease or loss of vision. Most of these patients had risk factors, in particular, a reduction in the ratio of the diameter of the excavation and the optic disc ("stagnant disk"), age over 50 years, diabetes, hypertension, coronary heart disease, hyperlipidemia and smoking. In the observational study, it was assessed whether the recent use of preparations of the class of PDE5 inhibitors with the acute onset of NPINZH was related.The results indicate an approximately 2-fold increase in the risk of NPIIV within 5 half-lives after the use of the PDE5 inhibitor. According to the published literature, the annual incidence of NPINZH is 2.5-11.8 cases per 100 000 men aged> 50 years in the general population. It should be recommended to patients in the event of a sudden loss of vision to stop sildenafil therapy and immediately consult a doctor. Persons who already had a case of NPINZ have an increased risk of recurrence of NPINZN. Therefore, the physician should discuss this risk with such patients, and discuss with them the potential risk of adverse effects of PDE5 inhibitors. PDE5 inhibitors, including sildenafil, these patients should be used with caution and only in situations where the expected benefit outweighs the risk.

    A small number of patients with hereditary pigment retinitis have genetically determined impairments of the functions of the retina phosphodiesterase. Information on the safety of sildenafil in patients with pigment retinitis is absent (see section "Contraindications").

    Hearing Impairment

    Some post-marketing and clinical studies report cases of sudden deterioration or hearing loss associated with the use of all PDE5 inhibitors, including sildenafil. Most of these patients had risk factors for sudden deterioration or loss of hearing. The causal relationship between the use of PDE5 inhibitors and sudden deterioration of hearing or loss of hearing is not established. In the event of a sudden deterioration in hearing or hearing loss, taking sildenafil should immediately consult a doctor.

    Bleeding

    Sildenafil enhances the antiplatelet effect of sodium nitroprusside, a donator of nitric oxide, on human platelets in vitro. Data on the safety of sildenafil in patients with a tendency to bleeding or exacerbation of peptic ulcer of the stomach and duodenum are absent, therefore sildenafil these patients should be used with caution (see section "C caution") The frequency of nasal bleeding in patients with pulmonary hypertension associated with diffuse connective tissue diseases was higher (sildenafil 12.9%, placebo 0%) than in patients with primary pulmonary hypertension (sildenafil 3.0%, placebo 2.4%). In patients who received sildenafil in combination with a vitamin K antagonist, the incidence of nasal bleeding was higher (8.8%) than in patients who did not take a vitamin K antagonist (1.7%).

    Application in conjunction with other treatments for erectile dysfunction The safety and efficacy of sildenafil, together with any other PDE5 inhibitors or other means of treating erectile dysfunction, have not been studied, so the use of such combinations is not recommended (see section "Contraindications").

    Effect on the ability to drive transp. cf. and fur:

    Since sildenafil may develop dizziness, decrease blood pressure, develop chromatopsy, blurred vision, and other side effects, caution should be exercised when driving vehicles and engaging in other potentially hazardous activities requiring increased attention and speed of psychomotor reactions. Also, you should carefully consider the individual effect of the drug in these situations, especially at the beginning of treatment and when changing the dosage regimen.

    Form release / dosage:

    Tablets dispersible in the oral cavity, 50 mg or 100 mg.

    Packaging:

    6 tablets per blister of aluminum foil with polymer coating VMCH / aluminum foil. 1 blister with instructions for use in a pack of cardboard.

    For 4 tablets in a blister of (PA / A1 / PVC) foil / / aluminum foil, laminated with PET / paper. 1 blister with instructions for use in a cardboard package.

    Storage conditions:At a temperature of no higher than 25 ° C.
    Keep out of the reach of children.
    Shelf life:

    3 years.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-003569
    Date of registration:14.04.2016
    Expiration Date:14.04.2021
    The owner of the registration certificate:Dr. Reddy's Laboratories Ltd.Dr. Reddy's Laboratories Ltd. India
    Manufacturer: & nbsp
    Representation: & nbspDr. Reddy`c Laboratoris Ltd.Dr. Reddy`c Laboratoris Ltd.
    Information update date: & nbsp28.06.2016
    Illustrated instructions
      Instructions
      Up